medicina61巻5号

2024年04月発行

特集 腎機能を考慮した内科疾患の診療 腎機能が病態・治療に関係する疾患 〈循環器疾患〉

Cardio-renal syndrome—体液調節と心・腎保護

著者： 増田貴博¹

所属機関： ¹自治医科大学腎臓内科学

ページ範囲：P.656 - P.661

Point
◎cardio-renal syndromeとは，心臓または腎臓の一方の機能障害が他方の機能障害を誘発する病態である．
◎体液量の必要度が正反対である心臓と腎臓の保護を両立させるためには，体液の適正化が重要である．
◎SGLT2阻害薬の長期的な体液適正化作用は，レニン-アンジオテンシン系および交感神経系の活性化抑制を介して心・腎保護に寄与する可能性がある．

参考文献

1）高島弘至，阿部雅紀：AKIの病態とその対応—心疾患とAKI．腎と透析94：35-39, 2023

2）Ronco C, et al：Cardio-renal syndromes；Report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31：703-711, 2010 PMID 20037146

3）日本救急医学会：不感蒸泄．　https://www.jaam.jp/dictionary/dictionary/word/0515.html（2024年1月閲覧）

4）増田貴博，長田太助：薬理学的基礎　利尿薬の種類と意義　SGLT2阻害薬—夜間多尿・頻尿を含めて．腎と透析90：729-734, 2021

5）Miura M, et al：Prognostic impact of loop diuretics in patients with chronic heart failure；Effects of addition of renin-angiotensin-aldosterone system inhibitors and beta-blockers. Circ J 80：1396-1403, 2016 PMID 27170200

6）Francis GS, et al：Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction（SOLVD）. Circulation 82：1724-1729, 1990 PMID 2146040

7）Vallon V, Verma S：Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 83：503-528, 2021 PMID 33197224

8）Masuda T, et al：Sodium-glucose cotransporter 2 inhibition with dapagliflozin ameliorates extracellular volume expansion in diabetic kidney disease patients. POJ Diabetes Obes 1：1-8, 2017

9）Ohara K, et al：The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr 12：37, 2020 PMID 32377235

10）Oka K, et al：Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease；The DAPA-BODY Trial. Front Med 10, 2023

11）Masuda T, Nagata D：Recent advances in the management of secondary hypertension；Chronic kidney disease. Hypertens Res 43：869-875, 2020

12）Masuda T, et al：SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. Am J Physiol Renal Physiol 323：F361-F369, 2022 PMID 32555327

13）Masuda T, et al：Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Renal Physiol 315：F653-F664, 2018 PMID 29790389

14）Masuda T, Nagata D：Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors；Novel insight for better cardio-renal outcomes in chronic kidney disease. Hypertens Res 46：1195-1201, 2023 PMID 36849579

15）Nuffield Department of Population Health Renal Studies Group；SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium：Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes；Collaborative meta-analysis of large placebo-controlled trials. Lancet 400：1788-1801, 2022 PMID 36351458